Victory Capital Management Inc Alaunos Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$99 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$0.12 - $0.5 $171 - $715	1,430 Added 6.04%	25,121 $3,000
Q2 2023 Jul 27, 2023	SELL	$0.43 - $0.65 $236 - $358	-551 Reduced 2.27%	23,691 $12,000
Q1 2023 May 02, 2023	SELL	$0.46 - $0.81 $144 - $254	-314 Reduced 1.28%	24,242 $15,000
Q4 2022 Feb 09, 2023	BUY	$0.5 - $261.0 $1,232 - $643,104	2,464 Added 11.15%	24,556 $15,000
Q3 2022 Nov 02, 2022	SELL	$1.04 - $322.5 $4,157 - $1.29 Million	-3,998 Reduced 15.32%	22,092 $38,000
Q2 2022 Aug 01, 2022	SELL	$0.41 - $1.24 $82 - $249	-201 Reduced 0.76%	26,090 $32,000
Q1 2022 May 04, 2022	SELL	$0.62 - $1.17 $464 - $876	-749 Reduced 2.77%	26,291 $14,000
Q4 2021 Feb 07, 2022	SELL	$1.09 - $1.89 $830 - $1,440	-762 Reduced 2.74%	27,040 $29,000
Q3 2021 Nov 02, 2021	BUY	$1.44 - $2.73 $912 - $1,730	634 Added 2.33%	27,802 $51,000
Q2 2021 Aug 03, 2021	SELL	$2.63 - $3.67 $1,009 - $1,409	-384 Reduced 1.39%	27,168 $72,000
Q1 2021 May 04, 2021	SELL	$2.82 - $5.6 $4,303 - $8,545	-1,526 Reduced 5.25%	27,552 $99,000
Q4 2020 Feb 01, 2021	BUY	$2.09 - $3.09 $3,137 - $4,638	1,501 Added 5.44%	29,078 $73,000
Q3 2020 Nov 09, 2020	SELL	$2.39 - $3.43 $3,843 - $5,515	-1,608 Reduced 5.51%	27,577 $69,000
Q2 2020 Aug 07, 2020	SELL	$2.2 - $3.71 $2,354 - $3,969	-1,070 Reduced 3.54%	29,185 $96,000
Q1 2020 May 04, 2020	SELL	$1.9 - $4.98 $46,170 - $121,014	-24,300 Reduced 44.54%	30,255 $74,000
Q4 2019 Feb 06, 2020	BUY	$3.95 - $5.35 $18,170 - $24,610	4,600 Added 9.21%	54,555 $257,000
Q4 2019 Feb 04, 2020	BUY	$3.95 - $5.35 $59,510 - $80,603	15,066 Added 43.18%	49,955 $197,000
Q3 2019 Nov 12, 2019	BUY	$4.13 - $6.94 $144,091 - $242,129	34,889 New	34,889 $149,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account